Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad289 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Matteo Franchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics and Quantitative Methods, Bicocca University Milan, 20126 Milan, Italy. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vifor Pharma.
Abstract (Originalsprache)
Context
Secondary hyperparathyroidism (SHPT) is a complication of chronic kidney disease (CKD) affecting mineral and bone metabolism and characterized by excessive parathyroid hormone (PTH) production and parathyroid hyperplasia.
Objective
The objective of this analysis was to compare the efficacy and adverse effects of extended-release calcifediol (ERC) and paricalcitol (PCT) by assessing their effect on the biomarkers PTH, calcium, and phosphate in patients with non-dialysis CKD (ND-CKD).
Methods
A systematic literature research was performed in PubMed to identify randomized control trials (RCTs). Quality assessment was done with the GRADE method. The effects of ERC vs PCT were compared using random effects in a frequentist setting.
Results
Nine RCTs comprising 1426 patients were included in the analyses. The analyses were performed on 2 overlapping networks, due to nonreporting of outcomes in some of the included studies. No head-to-head trials were identified. No statistically significant differences in PTH reduction were found between PCT and ERC. Treatment with PCT showed statistically significant increases in calcium compared with ERC (0.2 mg/dL increase; 95% CI, −0.37 to −0.05 mg/dL). No differences in effects on phosphate were observed.
Conclusion
This network meta-analysis showed that ERC is comparable in lowering PTH levels vs PCT. ERC displayed avoidance of potentially clinically relevant increases in serum calcium, offering an effective and well-tolerated treatment option for the management of SHPT in patients with ND-CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Statistics and Quantitative Methods, Bicocca University Milan, 20126 Milan, Italy.
- Quantify Research, 112 21 Stockholm, Sweden.
- Nephrology and Hypertension Clinic, Fundación Jiménez Díaz, 28040 Madrid, Spain.
- NOVA Medical School, Faculty of Medical Sciences, Nova University of Lisbon, 1169-056 Lisbon, Portugal.
- Department of Medicine, Huddinge, Karolinska Institutet, 141 57 Stockholm, Sweden.
ORCID-Profile: Matteo Franchi, Joel Gunnarsson, Giovanni Corrao
Förderung
- Vifor Pharma
Zitieren
APA
Franchi, M., Gunnarsson, J., Gonzales-Parra, E., Ferreira, A., Ström, O., & Corrao, G. (2023). Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad289
Vancouver
Franchi M, Gunnarsson J, Gonzales-Parra E, Ferreira A, Ström O, Corrao G. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad289
BibTeX
@article{Franchi2023,
author = {Franchi, Matteo and Gunnarsson, Joel and Gonzales-Parra, Emilio and Ferreira, Anibal and Ström, Oskar and Corrao, Giovanni},
title = {Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad289}
}
EUVIMED